PMID- 21034557
OWN - NLM
STAT- MEDLINE
DCOM- 20110308
LR  - 20211103
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 123
IP  - 17
DP  - 2010 Sep
TI  - Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on 
      interleukin-1beta-induced coronary artery in-stent restenosis in pigs.
PG  - 2405-9
AB  - BACKGROUND: Coronary artery in-stent restenosis (ISR) and late stent thrombosis 
      remain as important complications of stenting. The inflammation reactions to 
      sirolimus and paclitaxel-eluting stents were investigated in a swine stenosis 
      model induced by interleukin (IL)-1beta. METHODS: Mini pigs (n = 12; 2-3 months old 
      and weighing 25-30 kg) were subjected to thoracotomy. Segments (10 mm) of the mid 
      left anterior descending coronary artery and left circumflex coronary artery were 
      exposed and aseptically wrapped with a cotton mesh soaked with IL-1beta (5 microg). 
      After 2 weeks, the animals were anesthetized and quantitative coronary 
      arteriography (QCA) was performed. The stenosis sites were randomized into three 
      groups for stent insertion: a sirolimus-eluting stent (SES) group (Firebird(TM), 
      n = 7), a paclitaxel-eluting stent (PES) group (TAXUS(TM), n = 9), and a 
      bare-metal stent (BMS) group (YINYITM, Dalian Yinyi Biomaterials Development Co., 
      Ltd, China, n = 8). The three different stents were randomly implanted into 
      stenosis segments. Expression of monocyte chemoattractant protein-1 (MCP-1), 
      tumor necrosis factor-alpha (TNF-alpha), P-selectin and vascular cell adhesion 
      molecule-1 (VCAM-1) was determined by reverse transcription-coupled polymerase 
      chain reaction (RT-PCR). RESULTS: QCA showed severe stenosis in IL-1beta treated 
      segments. The SES and PES groups showed lower 1-month angiographic late lumen 
      loss (LLL) within the stent and the lesion compared with BMS (P < 0.05) by 
      follow-up QCA. The SES showed lower LLL than that of PES in reducing 1-month 
      inflammation lesions in pigs by follow-up QCA ((0.15 +/- 0.06) mm vs. (0.33 +/- 0.01) 
      mm, P < 0.0001). The neointimal hyperplasia areas in SES and PES showed lower 
      than those of BMS (SES (11.6 +/- 1.7) mm(2), PES (27.2 +/- 1.6) mm(2) vs. BMS (76.2 +/- 
      1.3) mm(2), P < 0.0001). The mRNA expression of MCP-1 by RT-PCR in SES and PES 
      showed lower than that of BMS at 30 days after stenting (SES 0.20 +/- 0.03, PES 
      0.48 +/- 0.49 vs. BMS 0.58 +/- 0.07, P < 0.05). Levels of VCAM-1 in SES were 
      significantly lower than those of PES and BMS (SES 0.35 +/- 0.08 vs. PES 0.65 +/- 
      0.13, BMS 0.70 +/- 0.06, P < 0.05). Histochemical immunostaining of vessel walls 
      showed lower inflammatory chemokine MCP-1 expression in the SES and PES groups 
      compared with BMS. CONCLUSION: SESs were superior in reducing 1-month 
      angiographic LLL in inflammation lesions in pigs, strongly suggesting that SESs 
      can suppress inflammatory reactions in ISR at multiple points.
FAU - Zhou, Xu-chen
AU  - Zhou XC
AD  - Department of Cardiology, First Affiliated Hospital of Dalian Medical University, 
      Dalian, Liaoning 116011, China.
FAU - Huang, Rong-chong
AU  - Huang RC
FAU - Zhang, Bo
AU  - Zhang B
FAU - Yin, Da
AU  - Yin D
FAU - Liang, Bin
AU  - Liang B
FAU - Wang, Shao-peng
AU  - Wang SP
FAU - Guan, Qi-gang
AU  - Guan QG
FAU - Sun, Xi-zhuo
AU  - Sun XZ
FAU - Miao, Zhi-lin
AU  - Miao ZL
FAU - He, Xue-zhi
AU  - He XZ
FAU - Han, Feng-tong
AU  - Han FT
FAU - Cheng, Ying
AU  - Cheng Y
FAU - Zhang, Li
AU  - Zhang L
FAU - Zeng, Ding-yin
AU  - Zeng DY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Interleukin-1beta)
RN  - P88XT4IS4D (Paclitaxel)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Animals
MH  - Coronary Restenosis/*prevention & control
MH  - Drug-Eluting Stents/*adverse effects
MH  - Inflammation/*prevention & control
MH  - Interleukin-1beta/*pharmacology
MH  - Male
MH  - Paclitaxel/*administration & dosage
MH  - Sirolimus/*administration & dosage
MH  - Swine
EDAT- 2010/11/03 06:00
MHDA- 2011/03/09 06:00
CRDT- 2010/11/02 06:00
PHST- 2010/11/02 06:00 [entrez]
PHST- 2010/11/03 06:00 [pubmed]
PHST- 2011/03/09 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2010 Sep;123(17):2405-9.